The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes
Open accessAbstract
BACKGROUND: The 65-kD isoform of glutamic acid decarboxylase (GAD) is a major autoantigen in patients with type 1 diabetes mellitus. This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age. METHODS: We randomly assigned 70 patients with type 1 diabetes who had fasting C-peptide levels above 0.1 nmol per liter (0.3 ng per milliliter) and GAD autoantibodies, recruited within 18 months after receiving the diagnosis of diabetes, to receive subcutaneous injections of 20 microg of GAD-alum (35 patients) or placebo (alum alone, 35 patients) on study days 1 and 30. At day 1 and months 3, 9, 15, 21, and 30, patients underwent a mixed-meal tolerance test to stimulate residual insulin secretion (measured as the C-peptide level). The effect of GAD-alum on the immune system was also studied. RESULTS: Insulin secretion gradually decreased in both study groups. The study treatment had no significant effect on change in fasting C-peptide level after 15 months (the primary end point). Fasting C-peptide levels declined from baseline levels significantly less over 30 months in the GAD-alum group than in the placebo group (-0.21 vs. -0.27 nmol per liter [-0.62 vs. -0.81 ng per milliliter], P=0.045), as did stimulated secretion measured as the area under the curve (-0.72 vs. -1.02 nmol per liter per 2 hours [-2.20 vs. -3.08 ng per milliliter per 2 hours], P=0.04). No protective effect was seen in patients treated 6 months or more after receiving the diagnosis. Adverse events appeared to be mild and similar in frequency between the two groups. The GAD-alum treatment induced a GAD-specific immune response. CONCLUSIONS: GAD-alum may contribute to the preservation of residual insulin secretion in patients with recent-onset type 1 diabetes, although it did not change the insulin requirement. (ClinicalTrials.gov number, NCT00435981.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GAD₆₅based therapies delivered via subcutaneous or intralymphatic administration have been tested in multiple clinical trials.[24][25][26] Overall efficacy in preserving insulin secretion was not shown.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Type 1 diabetes: new perspectives on disease pathogenesis and treatment
Atkinson, M. A., & Eisenbarth, G. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05415-0 · Cited by 1,491
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
Herold, K. C., Gitelman, S. E., Masharani, U. B., Hagopian, W., Bisikirska, B. C., DONALDSON, D. L., Rother, K. I., Diamond, B. E., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 641
Bækkeskov, S., Nielsen, J. H., Marner, B., Bilde, T., Ludvigsson, J., & Lernmark, Å. (1982) · Nature · doi:10.1038/298167a0 · Cited by 530
Self-citationRaz, I., Elias, D., Avron, A., Tamir, M., Metzger, M., & Cohen, I. R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06801-5 · Cited by 508
Randomisation and baseline comparisons in clinical trials
Altman, D. G., & Doré, C. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90014-v · Cited by 508
White, N. H., Cleary, P. A., Dahms, W. T., Goldstein, D. E., Malone, J. K., & Tamborlane, W. V. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.118887 · Cited by 458
Flagged first, then by citations
Research works printed but not linked: 3
- Dupre J, 1988, Diabetes Care, 11, 37
- Eisenbarth GS, 1985, Diabetes Res, 2, 271
- Daneman D, 1987, Clin Invest Med, 10, 484
Cited by
Sorted by citations
Items 401–500 of 520
(TCRαβ+) Double-Negative T Cells in Type 1 Diabetes Mellitus
Poddighe, D., Mussayeva, A., Dossybayeva, K., Zhubanova, G., Galiyeva, D., Le, K. L., & Tanko, N. M. (2025) · Cells · doi:10.3390/cells15010058 · Cited by 1
C-Peptid-Messung – Aktueller Stand der Analytik und klinische Anwendung
Müller‐Wieland, D., Schleicher, E. D., Niederau, C. M., Fritsche, A., Schwarz, T., Nauck, M. A., & Heinemann, L. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2785-7214 · Cited by 1
Tolerance and Autoimmunity in Type 1 Diabetes
Caro, V. D., Giannoukakis, N., & Trucco, M. (2011) · InTech eBooks · doi:10.5772/20651 · Cited by 1
Biologic therapies in type 1 diabetes: how far are they from us?
Deng, C., Xiang, Y., & Zhou, Z. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20132375 · Cited by 1
Moreira, D., Pais, I. P., Rebimbas, S., Barbosa, L., Rodrigues, L., Costa, C. S., & Campos, R. A. (2012) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.1016/s1646-3439(12)70004-4 · Cited by 1
Update on Care of Children with Type 1 Diabetes
Majidi, S., & Maahs, D. M. (2012) · Advances in Pediatrics · doi:10.1016/j.yapd.2012.04.007 · Cited by 1
Depleting T Cells in Newly Diagnosed Autoimmune (Type 1) Diabetes—Are We Getting Anywhere?
Lernmark, Å. (2013) · Diabetes · doi:10.2337/db13-1207 · Cited by 1
Evaluation of Preventive Studies in Type 1 Diabetes Mellitus
Arslan, M. S., Topaloğlu, O., Şahi̇n, M., & Delibaşı, T. (2013) · Endocrinology research and practice. · doi:10.4274/tjem.2124 · Cited by 1
Type 1 Diabetes Recurrence After Simultaneous Pancreas-Kidney Transplantation
Burke, G. W., Ciancio, G., Morsi, M., Figueiro, J., Chen, L., Vendrame, F., & Pugliese, A. (2018) · Current Transplantation Reports · doi:10.1007/s40472-018-0210-0 · Cited by 1
Immunotherapy for Autoimmune Diseases
Mali, A. V., Sawant, A., Mahadik, A., & Nair, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-9038-2_4 · Cited by 1
The Present and Future of Type 1 Diabetes Prevention: Teplizumab and Immunomodulators
Sohn, H., Kim, S., & Yoon, J.-H. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.4.210 · Cited by 1
Characterizing T-Cell Autoimmunity
Durinovic‐Belló, I., & Nepom, G. T. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-478-4_4 · Cited by 2
Tertiärprävention des Typ-1-Diabetes
Link, S., & Schloot, N. C. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0729-5 · Cited by 1
Immunopathogenesis of the NOD Mouse
Zhang, L., & Eisenbarth, G. S. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-478-4_12 · Cited by 1
Molecular-genetic, immunological bases and prophylaxis of diabetes mellitus in children
Титович, Е. В. (2011) · Problems of Endocrinology · doi:10.14341/probl20115719-18 · Cited by 1
Inmunoterapia en diabetes mellitus tipo 1. ¿Quo vadis?
Fernández-Balsells, M., Sojo-Vega, L., & Ricart, W. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.08.001 · Cited by 1
Type 1 Diabetes—Pathogenesis, Prediction, and Prevention
Baker, P. R., II, & Eisenbarth, G. S. (2009) · US Endocrinology · doi:10.17925/use.2009.05.1.79 · Cited by 1
Khudhair, S. A. (2013) · Cited by 1
Prevention of Autoimmune Disease
Harrison, L. C., & Wentworth, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00079-4 · Cited by 1
Immune Intervention for Type 1 Diabetes
Nambam, B., Bratina, N., & Schatz, D. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.2507 · Cited by 1
Development of therapeutic vaccine for life style-related diseases
Nakagami, H. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.154.270 · Cited by 1
Immunology of type 1 diabetes mellitus
Peakman, M. (2011) · doi:10.1093/med/9780199235292.003.1319 · Cited by 1
Type I Diabetes Mellitus in Children and Adolescents
Büyükinan, M. (2023) · doi:10.69860/nobel.9786053359111.27 · Cited by 1
Johnson, S. B. (2010) · Issues in clinical child psychology · doi:10.1007/978-1-4419-5800-6_12 · Cited by 1
Autoimmune Endocrine Disorders
Barker, J. M. (2013) · Humana Press eBooks · doi:10.1007/978-1-60761-395-4_31 · Cited by 1
Editorial Comment on type 1 diabetes and antigen-specific immunotherapy
Lernmark, Å., & Larsson, H. E. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02412.x · Cited by 1
Immune and cell therapy in type 1 diabetes: too little too late?
Gillard, P., & Mathieu, C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.560568 · Cited by 1
In light of recent clinical trial results, what lies next for Type 1 diabetes vaccine research?
Ludvigsson, J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.194 · Cited by 1
Self-citationType 1 Diabetes: Clinical and Experimental
Chiarelli, F., & Marcovecchio, L. (2010) · Yearbook of pediatric endocrinology · doi:10.1159/000320658 · Cited by 1
Immunological profile and aspects of immunotherapy in type 1 diabetes
Hjorth, M. (2010) · DiVA (Linkoping University) · Cited by 1
Self-citationDiabetes vaccines: review of the clinical evidence
Ludvigsson, J. (2011) · Clinical Investigation · doi:10.4155/cli.10.18 · Cited by 1
Self-citationACTA UNIVERSITATIS OULUENSIS D Medica 1372
Hekkala, A. (2016) · Cited by 1
Ambler, G. R., Cameron, F. J., Joshi, K., & Wherrett, D. K. (2019) · Wiley eBooks · doi:10.1002/9781119152712.ch15 · Cited by 1
Autoimmune Endocrine Disorders
Barker, J. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_35 · Cited by 1
Application of Classification Algorithms on IDDM Rat Data
Schmidt, R., Weiß, H., & Fuellen, G. (2012) · Lecture notes in computer science · doi:10.1007/978-3-642-31488-9_1
Immune profile from high-risk to onset of Type 1 diabetes
Rydén, A. (2011)
Understanding Pancreatic Secretion in Type 1 Diabetes
de Almeida, M. H., Matheus, A. S. D. M., & Lim, G. A. B. (2011) · InTech eBooks · doi:10.5772/24329
Diabetes in Childhood and Adolescence
Bilous, F. R., & Donnelly, R. (2010) · Wiley eBooks · doi:10.1002/9781444391374.ch28
TYPE 1 DIABETES - THE AUTOIMMUNE PROCESS AND ISLET TRANSPLANTATION
Jacobson, S. (2010) · Figshare
Targeted Therapies in Autoimmune and Inflammatory Skin Disorders
Eming, R., & Tarner, I. H. (2011) · Springer eBooks · doi:10.1007/978-3-211-99225-8_24
Perspectives of Cell Therapy in Type 1 Diabetes
Maria, M., Cantaluppi, V., Favaro, E., Camussi, E., Deregibus, M. C., & Camussi, G. (2011) · InTech eBooks · doi:10.5772/22261
Immunotherapies for Type 1 Diabetes
Gürr, W. (2013) · InTech eBooks · doi:10.5772/54717
Physical activity and diabetic complications in patients with type 1 diabetes
Wadén, J. (2010) · Työväentutkimus Vuosikirja
Hart, N. J. (2013) · UA Campus Repository (The University of Arizona)
Diabetes mellitus in Adults - Aspects of Incidence, Autoimmunity and C-peptide
Thunander, M. (2011) · Lund University Publications (Lund University)
Modulation of TCR signals reprograms immune tolerance in transplantation and type-1 diabetes
Khattar, M. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Islet antigen-specific T cells and regulatory T cells in type 1 diabetes
Öling, V. (2010) · UTUPub (University of Turku)
Lee, M., & Kim, K. (2009) · Journal of Korean Medical Association · doi:10.5124/jkma.2009.52.7.677
Antigen specific treatment for the inhibition and remission of type 1 diabetes
Abiru, N. (2008) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.31.432
Update van de farmacotherapeutische opties bij diabetes op kinderleeftijd
Chiarelli, F., & Marcovecchio, L. (2014) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-014-0023-4
Studies of Mucosal Immune Regulation in Celiac Disease and Type 1 Diabetes
Lahdenperä, A. I. (2014) · Linköping University Electronic Press eBooks · doi:10.3384/diss.diva-110687
Characteristics of GADA in Type 1 Diabetes following Immunomodulation with GAD65
Chéramy, M. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Self-citationAutoantibodies related to type 1 diabetes in children
Skoglund, C. (2011) · DiVA (Linkoping University)
Genetics of type 1 diabetes: recent progress and future perspectives
Wägner, A. M., & Wiebe, J. C. (2009) · Avances en Diabetología
Schulte, B. M. (2010) · Radboud Repository (Radboud University)
Sanjeevi, C. B., & Sun, C. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_19
Nieuwe inzichten in therapeutische mogelijkheden bij diabetes mellitus type 1
van Heiningen, J., Keij, F. M., & Roep, B. O. (2015) · Tijdschrift voor kindergeneeskunde · doi:10.1007/s12456-015-0004-6
Chéramy, M., Skoglund, C., Johansson, I., Ludvigsson, J., Hampe, C. S., & Casas, R. (2010)
Self-citationTerapia antigenica con GAD65 nel diabete mellito di tipo 1 di recente diagnosi
Ludvigsson, J., Krisky, D. M., Casas, R., Battelino, T., Castaño, L., Greening, J. E., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J., et al. (2012) · L Endocrinologo · doi:10.1007/bf03344894
Self-citationWan, X. (2013) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/43262
Another Treatment for Type 1 Diabetes
Bauchner, H. (2008) · Journal watch · doi:10.1056/pa200810220000002
[(R)evolution in pediatric diabetology].
Dorchy, H. (2010) · PubMed
Ludvigsson, J. (2016) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2016.03.00063
Self-citationType 1 Diabetes: Past, Present, and Future Therapies
Singh, P., Kokil, G. R., Tupally, K. R., Poddar, K., Tan, A., Venkatesan, T., Parekh, H. S., & Pastorin, G. (2016) · SpringerBriefs in applied sciences and technology · doi:10.1007/978-981-10-0602-9_4
Aspects of the Pre-Diabetic Period in Type 1 Diabetes
Åkerman, L. (2016) · Linköping University medical dissertations · doi:10.3384/disss.diva-132171
Insulin and Immunotherapy in Children and Adolescents with Type 1 Diabetes
Ludvigsson, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-40242-0_3
Self-citationCo nowego w terapii cukrzycy typu 1
Noczyńska, A., Zubkiewicz‐Kucharska, A., & Nocoń-Bohusz, J. (2012) · Family Medicine & Primary Care Review
Cloning and characterization of IA-2 specific autoantibodies in Type 1 diabetes
Johnson, C. (2016) · Research Portal (King's College London)
Therapeutic uses of stem cells in endocrinology.
Nasli‐Esfahani, E., Ghavamzadeh, A., & Larijani, B. A. (2014) · Iranian Journal of Public Health
Antigen-specific immunotherapy and influenza vaccination in type 1 diabetes: timing is everything
Yeo, L., & Peakman, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4304-5
Nanopartículas de insulina para administração oral
Correia, C. J. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Bueno, A. B., Castaño, A. M., & Rodríguez, Á. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch6
Type 1 Diabetes Mellitus: Immune Intervention
Skyler, J. S. (2012) · Wiley eBooks · doi:10.1002/9781118321508.ch9
Skyler, J. S. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch37
Pediatric Diabetes: Review Article
Bavishna, B., Devi, R. U., & Krishnan, S. G. (2019) · Indian Journal of Public Health Research & Development · doi:10.5958/0976-5506.2019.04013.0
Physiopathologie des états diabétiques
(2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70868-8.50002-5
Physiopathologie des états diabétiques
(2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00002-0
Introduction: specific disease areas
Rose, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-823888-2.00021-1
Tracking the humoral immune response in type 1 diabetes
Bian, X. (2015)
Gluten peptide immunomodulatory strategies
Vitale, S., Picascia, S., & Gianfrani, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821594-4.00009-8
Ishizuka, A. S., Lynn, G. M., & Jewell, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821440-4.00002-5
GAD65 An Immunomodulator in Type 1 Diabetes
Axelsson, S. (2012) · DiVA (Linkoping University)
Self-citationEl ordenamiento juridico informativo en España
Guanter, J. M. D. (1990) · Situación: revista de coyuntura económica
Immunotherapy for Type 1 Diabetes
Dayan, C. M., & Tatović, D. (2022) · doi:10.1093/med/9780198870197.003.0257
Skyler, J. S. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_15
Future Drug Treatment for Type 1 Diabetes
Larsson, H. E., Delli, A. J., Ivarsson, S. A., & Lernmark, Å. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch59
Self-citationType 1 (Insulin-Dependent) Diabetes Mellitus
Delli, A. J., & Lernmark, Å. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00040-x
von Herrath, M., & Sarikonda, G. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1279979.747083
(2012) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2012.1232
Physiopathologie des états diabétiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00002-6
Prevention of Autoimmune Disease: The Type 1 Diabetes Paradigm
Harrison, L. C., & Wentworth, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00070-1
Rhee, S. Y., & Kim, Y. S. (2009) · Korean Diabetes Journal · doi:10.4093/kdj.2009.33.1.1
Zampetti, S., & Buzzetti, R. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_9-1
Sanjeevi, C. B., & Sun, C. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_19-2
(2012) · Elsevier eBooks · doi:10.1016/b978-3-437-41797-9.16001-7
Recurrence of Type 1 Diabetes Mellitus
Burke, G. W., Ciancio, G., Morsi, M., Figueiro, J., Chen, L., Sageshima, J., Vendrame, F., & Pugliese, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_56
Grosembacher, L., Pereyra-Bonnet, F., Muratore, C., Pomares, M. L., Avila, P., Retamosa, J., Cuzziol, G. E., Maldini, A. C., Marco, R. D., Apoloni, S. B., et al. (2023) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v49i3.635
Immunotherapies for Type 1 Diabetes
Johannesen, J., & Pociot, F. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch76
Az 1-es típusú diabetes mellitus immunterápiája
Kiss, K. A., Tóth, A., Schandl, L., Kiss, Z., Winkler, G., & Kis, J. T. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33000
Metadata
- Authors
- Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., Lindh, A., Nilsson, N.-Ö., Åman, J., Örtqvist, E., Zerhouni, P., & Casas, R.
- Affiliations
- Linköping University (SE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-30
- Volume
- 359
- Issue
- 18
- Pages
- 1909-1920
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2041637201
- Cited by
- 520
- References
- 32
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 13 · 2023: 13 · 2022: 15 · 2021: 16 · 2020: 21 · 2019: 10 · 2018: 14 · 2017: 12 · 2016: 26 · 2015: 20 · 2014: 28 · 2013: 55 · 2012: 51
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, glutamic acid decarboxylase, glutamic acid decarboxylase antibodies, residual insulin secretion, C-peptide, recent-onset diabetes, autoimmunity, mixed meal tolerance test
- MeSH terms
- Insulin Secretion, Adolescent, Analysis of Variance, Autoantibodies, C-Peptide, Child, Diabetes Mellitus, Type 1, Female, Glutamate Decarboxylase, Humans, Hypoglycemic Agents, Immunotherapy, Injections, Subcutaneous, Insulin, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
